RxDoctor Payments Data

Ravi Krishnan, MD

Internal Medicine · Mayfield Village, OHNPI 1306836150

Payments from drug & device makers

$10,748in general payments, 2019–2025

Across 643 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$876
  • Pfizer$795
  • Novo Nordisk$718
  • Boehringer Ingelheim$713
  • Amgen$521
  • plus $6K from 44 others

What the payments were for

  • Food & beverage$10,66599%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,748 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$317,005
Medicare patients
914
Services billed
3,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban584$293,925
IngrezzaValbenazine Tosylate69$203,422
JanuviaSitagliptin Phosphate237$146,357
JardianceEmpagliflozin77$99,666
XareltoRivaroxaban194$78,670
FarxigaDapagliflozin Propanediol73$49,963
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$41,951
GlatopaGlatiramer Acetate14$34,075
CreonLipase/Protease/Amylase37$33,384
NuedextaDextromethorphan Hbr/Quinidine36$27,529
EntrestoSacubitril/Valsartan40$23,687
OzempicSemaglutide20$19,628
TradjentaLinagliptin39$19,347
Breo ElliptaFluticasone/Vilanterol26$13,336
Pantoprazole Sodium544$13,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$795$300,168604 claims
MerckJanuvia$419$146,357237 claims
Boehringer IngelheimJardiance, Tradjenta$713$119,012116 claims
Johnson & JohnsonXarelto$246$78,670194 claims
GSKTrelegy Ellipta, Breo Ellipta$359$55,28783 claims
AstraZenecaFarxiga, Brilinta$1,500$54,34492 claims
AbbVieCreon, Synthroid$876$38,100118 claims
Avanir Pharmaceuticals, Inc.Nuedexta$56$27,52936 claims
NovartisEntresto$499$23,68740 claims
Novo NordiskOzempic$718$19,62820 claims
Otsuka America Pharmaceutical, Inc.Rexulti$335$9,75811 claims
Astellas Pharma US IncMyrbetriq$186$7,93524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Mayfield Village

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →